ClinicalTrials.gg
CompletedNCT03066609Updated Dec 30, 2019Results posted

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

A Phase 3 interventional study of Secukinumab 150 mg s.c. and Secukinumab 300 mg s.c. in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-30.

Primary conditionPsoriasisRegistry: Skin DiseasesReclassifiedWhy we changed it
Registry
Skin Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Psoriasis
Why
  1. The study's listed conditions name Psoriasis, a narrower term within Skin Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
543
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
8th of 54
543 · median 124
Started
2017
with 4 others
Phase 3
24 of 54
none open now
Registered
37th of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one is the 8th largest by enrollment, is one of 5 that started in 2017, is one of 24 in phase 3, and was the 37th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Plaque psoriasis
  • Secukinumab
  • Skin condition
  • skin disease
  • itching
  • psoriasis vulgaris
  • immune-mediated systemic disease
  • skin lesions
  • scaly patches
  • papules
  • psoriasis
04

In context

Psoriasis Reclassified

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

This study's enrollment of 543 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Psoriasis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must give a written, signed and dated .
  2. Men or women at least 18 years of age at time of screening.
  3. Chronic plaque-type psoriasis present for at least 6 months and diagnosed before Baseline.
  4. Moderate to severe psoriasis as defined at Baseline by:

    • PASI score of 12 or greater, and
    • IGA mod 2011 score of 3 or greater (based on a static scale of 0 - 4), and
    • Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.
  5. Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by

    • topical treatment and/or,
    • phototherapy and/or,
    • previous systemic therapy.

Exclusion criteria

Exclusion Criteria:

  1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at Screening or Baseline.
  2. Drug-induced psoriasis.
  3. Ongoing use of prohibited treatments.
  4. Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the IL-17 receptor.
  5. Use of other drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.
  6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
543 participants (actual)

Study arms

  • Experimental
    Secukinumab 150mg

    Secukinumab 150mg s.c.

    Drug: Secukinumab 150 mg s.c.

  • Experimental
    Secukinumab 300mg

    Secukinumab 300mg s.c.

    Drug: Secukinumab 300 mg s.c.

  • Placebo comparator
    Placebo

    Placebo to secukinumab s.c

    Drug: Placebo

Interventions

  • 150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48

  • 300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48

  • DrugPlacebo

    Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48

07

What researchers measure

Primary outcomes

  1. Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation)

    Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: Week 12

  2. Investigator's Global Assessment (IGA) Mod 2011 0/1 (Multiple Imputation)

    Investigator assessed disease using a validated scale (IGA mod 2011) and rate the disease from a score of 0 (clear skin) to 4 (severe disease). result given in terms of count of participants with response in 100 imputations. The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.

    Time frame: Week 12

Secondary outcomes

  1. Psoriasis Area and Severity Index (PASI) 90 (Multiple Imputation)

    Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: Week 12

  2. Efficacy of Secukinumab in Maintaining PASI 75 Response at Week 52 in Subjects Who Were PASI 75 Responders at Week 12 (Multiple Imputation)

    Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: Week 52

  3. Efficacy of Secukinumab in Maintaining IGA Mod 2011 0 or 1 Response at Week 52 in Subjects Who Were IGA Mod 2011 0 or 1 Responders at Week 12 (Multiple Imputation)

    Investigator assessed disease using a validated scale (IGA mod 2011) and rate the disease from a score of 0 (clear skin) to 4 (severe disease). result given in terms of count of participants with response in 100 imputations. The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.

    Time frame: Week 52

  4. PASI 50/75/90/100 and IGA Mod 2011 0 or 1 Response Over Time (Multiple Imputation)

    Number (%) of subjects with PASI 50, PASI 75, PASI 90, PASI 100 and IGA mod 2011 0 or 1 response

    Time frame: week 1, week 12, week 24, week 52

  5. American Collage of Rheumatology (ACR) Response 20/50/70

    Percentage of patients who achieved ACR 20/50/70 at Week 12 and up to Week 52. The subset of patients who had active PsA at baseline included 7 patients in the secukinumab 150 mg group, 17 patients in the secukinumab 300 mg group and 4 patients in the placebo group. ACR 20, 50 or 70 responses correspond, respectively, to at least 20%, 50% or 70% improvement in comparison with baseline in the number of tender and swollen joint counts, in addition to similar improvements in at least three of five other measure of disability or disease activity

    Time frame: week 12, week 24, week 52

  6. Time to PASI 75 Response up to Week 12

    Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

    Time frame: week 12

08

Results

Posted Dec 30, 2019

Participant flow

A total of 664 patients were screened and 543 patients were randomized to one of three treatment groups in the induction period: secukinumab 300 mg (n=272), secukinumab 150 mg (n=136), and placebo (n=135)

INDUCTION
Participant flow — INDUCTION
MilestoneSecukinumab 150mgSecukinumab 300mgPlaceboPlacebo - Secukinumab 300mg
Started1362721350
Completed1342701330
Not completed2220
Withdrew: Pregnancy0010
Withdrew: Lack of efficacy0010
Withdrew: Adverse event2200
MAINTENANCE
Participant flow — MAINTENANCE
MilestoneSecukinumab 150mgSecukinumab 300mgPlaceboPlacebo - Secukinumab 300mg
Started1342704129
Completed1272662126
Not completed7423
Withdrew: Adverse event0001
Withdrew: Withdrawal by subject4211
Withdrew: Lost to follow-up0110
Withdrew: Pregnancy1000
Withdrew: Lack of efficacy2101
OVERALL STUDY
Participant flow — OVERALL STUDY
MilestoneSecukinumab 150mgSecukinumab 300mgPlaceboPlacebo - Secukinumab 300mg
Started1362726129
Completed1262642124
Not completed10845
Withdrew: Adverse event2201
Withdrew: Withdrawal by subject4212
Withdrew: Lost to follow-up1111
Withdrew: Pregnancy1010
Withdrew: Lack of efficacy2111
Withdrew: Discontinued follow up0200

Outcome measures

PrimaryPsoriasis Area and Severity Index (PASI) 75 (Multiple Imputation)

Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation)
ParticipantsSecukinumab 150mgSecukinumab 300mgPlacebo
Psoriasis Area and Severity Index (PASI) 75 (Multiple Imputation)1122546
Statistical analysis
  • Secukinumab 150mg vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 153.94 · 95% CI 54.02 to 438.67
  • Secukinumab 300mg vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 557.98 · 95% CI 187.2 to 1663.4
PrimaryInvestigator's Global Assessment (IGA) Mod 2011 0/1 (Multiple Imputation)

Investigator assessed disease using a validated scale (IGA mod 2011) and rate the disease from a score of 0 (clear skin) to 4 (severe disease). result given in terms of count of participants with response in 100 imputations. The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Investigator's Global Assessment (IGA) Mod 2011 0/1 (Multiple Imputation)
ParticipantsSecukinumab 150mgSecukinumab 300mgPlacebo
Investigator's Global Assessment (IGA) Mod 2011 0/1 (Multiple Imputation)922144
Statistical analysis
  • Secukinumab 150mg vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 75.82 · 95% CI 25.81 to 222.72
  • Secukinumab 300mg vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 149.71 · 95% CI 51.83 to 432.42
SecondaryPsoriasis Area and Severity Index (PASI) 90 (Multiple Imputation)

Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Psoriasis Area and Severity Index (PASI) 90 (Multiple Imputation)
ParticipantsSecukinumab 150mgSecukinumab 300mgPlacebo
Psoriasis Area and Severity Index (PASI) 90 (Multiple Imputation)852102
Statistical analysis
  • Secukinumab 150mg vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 114.85 · 95% CI 26.94 to 489.59
  • Secukinumab 300mg vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 246.12 · 95% CI 58.41 to 1037.1
SecondaryEfficacy of Secukinumab in Maintaining PASI 75 Response at Week 52 in Subjects Who Were PASI 75 Responders at Week 12 (Multiple Imputation)

Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
Week 52
Reported as:
Count of participants · Participants
Efficacy of Secukinumab in Maintaining PASI 75 Response at Week 52 in Subjects Who Were PASI 75 Responders at Week 12 (Multiple Imputation)
ParticipantsSecukinumab 150mgSecukinumab 300mg
Efficacy of Secukinumab in Maintaining PASI 75 Response at Week 52 in Subjects Who Were PASI 75 Responders at Week 12 (Multiple Imputation)94235
SecondaryEfficacy of Secukinumab in Maintaining IGA Mod 2011 0 or 1 Response at Week 52 in Subjects Who Were IGA Mod 2011 0 or 1 Responders at Week 12 (Multiple Imputation)

Investigator assessed disease using a validated scale (IGA mod 2011) and rate the disease from a score of 0 (clear skin) to 4 (severe disease). result given in terms of count of participants with response in 100 imputations. The Investigator's Global Assessment (IGA) mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Efficacy of Secukinumab in Maintaining IGA Mod 2011 0 or 1 Response at Week 52 in Subjects Who Were IGA Mod 2011 0 or 1 Responders at Week 12 (Multiple Imputation)
ParticipantsSecukinumab 150mgSecukinumab 300mg
Efficacy of Secukinumab in Maintaining IGA Mod 2011 0 or 1 Response at Week 52 in Subjects Who Were IGA Mod 2011 0 or 1 Responders at Week 12 (Multiple Imputation)65162
SecondaryPASI 50/75/90/100 and IGA Mod 2011 0 or 1 Response Over Time (Multiple Imputation)

Number (%) of subjects with PASI 50, PASI 75, PASI 90, PASI 100 and IGA mod 2011 0 or 1 response

Time frame:
week 1, week 12, week 24, week 52
Reported as:
Count of participants · Participants
PASI 50/75/90/100 and IGA Mod 2011 0 or 1 Response Over Time (Multiple Imputation)
ParticipantsSecukinumab 150mgSecukinumab 300mgPlaceboPlacebo - AIN457 300 mg
Week 1 IGA 0/10100
Week 1 PASI 5052510
Week 1 PASI 750000
Week 1 PASI 900000
Week 1 PASI 1000000
Week 12 IGA 0/19221440
Week 12 PASI 50130267160
Week 12 PASI 7511225460
Week 12 PASI 908521020
Week 12 PASI 100288110
Week 16 IGA 0/1100219232
Week 16 PASI 501342704108
Week 16 PASI 75124261372
Week 16 PASI 9098233222
Week 16 PASI 100399903
Week 24 IGA 0/191217188
Week 24 PASI 501352714123
Week 24 PASI 751232572113
Week 24 PASI 9093230294
Week 24 PASI 10047107031
Week 52 IGA 0/179194096
Week 52 PASI 501282694126
Week 52 PASI 751112594119
Week 52 PASI 90862181101
Week 52 PASI 10042110155
SecondaryAmerican Collage of Rheumatology (ACR) Response 20/50/70

Percentage of patients who achieved ACR 20/50/70 at Week 12 and up to Week 52. The subset of patients who had active PsA at baseline included 7 patients in the secukinumab 150 mg group, 17 patients in the secukinumab 300 mg group and 4 patients in the placebo group. ACR 20, 50 or 70 responses correspond, respectively, to at least 20%, 50% or 70% improvement in comparison with baseline in the number of tender and swollen joint counts, in addition to similar improvements in at least three of five other measure of disability or disease activity

Time frame:
week 12, week 24, week 52
Reported as:
Count of participants · Participants
American Collage of Rheumatology (ACR) Response 20/50/70
ParticipantsSecukinumab 150mgSecukinumab 300mgPlaceboPlacebo - AIN457 300 mg
Week 12 ACR 2041300
Week 12 ACR 5031200
Week 12 ACR 702600
Week 24 ACR 2051402
Week 24 ACR 5041001
Week 24 ACR 702601
Week 52 ACR 2041303
Week 52 ACR 5031102
Week 52 ACR 702800
SecondaryTime to PASI 75 Response up to Week 12

Psoriasis Area and Severity Index (PASI) was assessed/calculated as per usual standard. result given in terms of count of participants with response in 100 imputations. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).

Time frame:
week 12
Reported as:
Median · days
Time to PASI 75 Response up to Week 12
daysSecukinumab 150mgSecukinumab 300mg
Time to PASI 75 Response up to Week 1257 (51 to 57)55 (29 to 57)

Adverse events

Collected over 12 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 150 mg0/136 (0%)5/136 (3.7%)115/136 (84.6%)
AIN457 300 mg0/272 (0%)9/272 (3.3%)221/272 (81.3%)
Any AIN457 300 mg0/401 (0%)14/401 (3.5%)312/401 (77.8%)
Any AIN457 Dose0/537 (0%)19/537 (3.5%)427/537 (79.5%)
Placebo0/135 (0%)2/135 (1.5%)71/135 (52.6%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventAIN457 150 mgAIN457 300 mgAny AIN457 300 mgAny AIN457 DosePlacebo
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1360/2720/4010/5371/135
PsoriasisSkin and subcutaneous tissue disorders0/1360/2720/4010/5371/135
Angina unstableCardiac disorders1/1360/2720/4011/5370/135
Arteriosclerosis coronary arteryCardiac disorders1/1360/2721/4012/5370/135
Crohn's diseaseGastrointestinal disorders1/1360/2720/4011/5370/135
Tooth impactedGastrointestinal disorders1/1360/2720/4011/5370/135
AppendicitisInfections and infestations0/1362/2722/4012/5370/135
TonsillitisInfections and infestations1/1360/2720/4011/5370/135
Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1360/2720/4011/5370/135
Erythrodermic psoriasisSkin and subcutaneous tissue disorders1/1360/2720/4011/5370/135
Most frequent other events
Showing 10 of 26
Most frequent other events
EventAIN457 150 mgAIN457 300 mgAny AIN457 300 mgAny AIN457 DosePlacebo
Upper respiratory tract infectionInfections and infestations41/13667/27297/401138/53713/135
HyperuricaemiaMetabolism and nutrition disorders25/13656/27276/401101/53717/135
NasopharyngitisInfections and infestations15/13644/27257/40172/5375/135
InfluenzaInfections and infestations17/13628/27238/40155/5374/135
Oropharyngeal painRespiratory, thoracic and mediastinal disorders16/13625/27232/40148/5373/135
PruritusSkin and subcutaneous tissue disorders12/13632/27236/40148/53711/135
DiarrhoeaGastrointestinal disorders13/13631/27242/40155/53712/135
PharyngitisInfections and infestations14/13624/27235/40149/5377/135
CoughRespiratory, thoracic and mediastinal disorders13/13617/27225/40138/5372/135
UrticariaSkin and subcutaneous tissue disorders12/13624/27230/40142/5370/135

Baseline characteristics

Age, Continuous
Age, Continuous(years)Secukinumab 150mgSecukinumab 300mgPlaceboTotal
Mean41 ± 11.3939.9 ± 12.3540.1 ± 11.0140.2 ± 11.78
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 150mgSecukinumab 300mgPlaceboTotal
Female376727131
Male99205108412
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab 150mgSecukinumab 300mgPlaceboTotal
East Asian109220109438
Southeast Asian19321667
South Asian1001
West Asian0303
other6171033
not reported1001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab 150mgSecukinumab 300mgPlaceboTotal
Caucasian7201037
Asian129252125506
09

Study locations

32 sites
  • Novartis Investigative Site
    Beijing, Beijing 100039, China
  • Novartis Investigative Site
    Xicheng Direct, Beijing 100044, China
  • Novartis Investigative Site
    Wuhan, Hubei 430030, China
  • Novartis Investigative Site
    Chang Chun, Jilin 130021, China
  • Novartis Investigative Site
    Dalian, Liaoning 116011, China
  • Novartis Investigative Site
    Shenyang, Liaoning 110000, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310009, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310014, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310016, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Guang Zhou, 510080, China
  • Novartis Investigative Site
    Guangzhou, 510000, China
  • Novartis Investigative Site
    Nanjing, 210042, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Shanghai, 200433, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Kecskemet, Bacs Kiskun 6000, Hungary
  • Novartis Investigative Site
    Kaposvar, 7400, Hungary
  • Novartis Investigative Site
    Oroshaza, 5900, Hungary
  • Novartis Investigative Site
    Batu Caves, 68100, Malaysia
  • Novartis Investigative Site
    Penang, 10990, Malaysia
  • Novartis Investigative Site
    Makati City, 1220, Philippines
  • Novartis Investigative Site
    Quezon City, 1102, Philippines
  • Novartis Investigative Site
    Bangkoknoi, Bangkok 10700, Thailand
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Aydin, 09100, Turkey
  • Novartis Investigative Site
    Izmir, 35340, Turkey
  • Novartis Investigative Site
    Manisa, 45040, Turkey
  • Novartis Investigative Site
    Mersin, 33079, Turkey
  • Novartis Investigative Site
    Pendik / Istanbul, 34899, Turkey
10

References and documents

Publications

  • Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, Zhang SF, Xu JH, Li CX, Cheng H, Guo Q, Pan WL, Li SQ, Li RY, Guo ZP, Song ZQ, Li SS, Dong XQ, Wang L, Fu R, Regnault P, Charef P, Mazur R, Patekar M. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis. Chin Med J (Engl). 2020 Nov 20;133(22):2665-2673. doi: 10.1097/CM9.0000000000001163. PubMed 33060370 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Dec 2017, 9 months.

Results were first posted in Dec 2019, 2 years after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2017
First posted
Feb 28, 2017
StartActual
Feb 28, 2017
Primary completionActual
Dec 21, 2017
CompletionActual
Nov 20, 2018
Results first posted
Dec 30, 2019
Last update
Dec 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03066609
Responsible party
Sponsor
First posted
Feb 28, 2017
Start date
Feb 28, 2017
Primary completion
Dec 21, 2017
Completion
Nov 20, 2018
Results posted
Dec 30, 2019
Last update
Dec 30, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion